[New aspects of current therapeutic strategies in oropharyngeal carcinoma: highlights of the 2012 ASCO meeting].
Standard
[New aspects of current therapeutic strategies in oropharyngeal carcinoma: highlights of the 2012 ASCO meeting]. / Löwenthal, Maureen; Vitez, Edina; Laban, Simon; Münscher, Adrian; Güldenzoph, Björn; Knecht, Rainald; Busch, Chia-Jung.
In: HNO, Vol. 60, No. 11, 11, 2012, p. 951-956.Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - [New aspects of current therapeutic strategies in oropharyngeal carcinoma: highlights of the 2012 ASCO meeting].
AU - Löwenthal, Maureen
AU - Vitez, Edina
AU - Laban, Simon
AU - Münscher, Adrian
AU - Güldenzoph, Björn
AU - Knecht, Rainald
AU - Busch, Chia-Jung
PY - 2012
Y1 - 2012
N2 - Beside the surgical treatment of head and neck cancer, the concept of organ and function preserving therapy of locally advanced HNSCC (head and neck squamous cell carcinoma) especially of oropharyngeal origin is becoming increasingly important. The comparison of induction chemotherapy plus chemoradiation and primary concomitant chemoradiation has recently been the subject of randomized clinical trials. New combinations of different (chemo)radiation regimens and targeted therapies are also under investigation for HNSCC. Molecular markers predicting treatment efficacy as well as new potential targets are also being evaluated in several clinical trials. The good prognosis of HPV-associated HNSCC has sparked efforts to deintensify treatment to minimize therapy-related toxicities. The impact of specific therapies is growing due to the increasing incidence of young patients with HPV-positive carcinomas.
AB - Beside the surgical treatment of head and neck cancer, the concept of organ and function preserving therapy of locally advanced HNSCC (head and neck squamous cell carcinoma) especially of oropharyngeal origin is becoming increasingly important. The comparison of induction chemotherapy plus chemoradiation and primary concomitant chemoradiation has recently been the subject of randomized clinical trials. New combinations of different (chemo)radiation regimens and targeted therapies are also under investigation for HNSCC. Molecular markers predicting treatment efficacy as well as new potential targets are also being evaluated in several clinical trials. The good prognosis of HPV-associated HNSCC has sparked efforts to deintensify treatment to minimize therapy-related toxicities. The impact of specific therapies is growing due to the increasing incidence of young patients with HPV-positive carcinomas.
KW - Humans
KW - Medical Oncology/trends
KW - Oropharyngeal Neoplasms/therapy
KW - Humans
KW - Medical Oncology/trends
KW - Oropharyngeal Neoplasms/therapy
M3 - SCORING: Zeitschriftenaufsatz
VL - 60
SP - 951
EP - 956
JO - HNO
JF - HNO
SN - 0017-6192
IS - 11
M1 - 11
ER -
